Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNY4 pseudogene 19 (RNY4P19) is a genomic pseudogene annotated as a non-coding RNA locus highly homologous to the functional Y RNA RNY4. Pseudogenes like RNY4P19 typically arise by duplication or retrotransposition of a parent gene (in this case, RNY4), but do not encode functional RNA or protein products. There is no evidence that RNY4P19 is transcribed or has a documented biological function or clinical role. Research has primarily focused on functional Y RNAs (such as RNY4), which participate in RNA quality control, DNA replication initiation, and may act as exosome-contained non-coding RNAs with potential cancer biomarker relevance[1][4]. Some Y RNA pseudogenes, including those very similar to RNY4P19, contribute non-specifically to RNA-seq alignments due to high sequence similarity, but this does not reflect an independent function. As of current knowledge, RNY4P19 itself is not a recognized therapeutic target and is mostly relevant as a reference point in genomic or transcriptomic analysis. Key clarification: - RNY4P19 is a *pseudogene* and is not the same as the *functional RNY4 gene*, which is under active investigation for its role as an exosomal RNA biomarker and potential participant in tumor microenvironment modulation[1][4]. - Pseudogenes (including RNY4P19) sometimes participate in post-transcriptional regulation as miRNA decoys or via antisense transcripts, but no such role is yet known or described for RNY4P19[2]. - In transcriptome or exosome studies, reads may non-specifically align to RNY4P19 or related pseudogenes due to sequence homology, but this does not imply targetability or functional disease association[1][4]. Conclusion: - RNY4P19 is a pseudogene, not a therapeutic target, and should be distinguished from the functional roles attributed to RNY4 or its processed RNA fragments[1][4][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, Ro-associated Y4 pseudogene 19 (RNY4P19).